Fig. No.	Figure Captions	Page No.
1.1	Chemical classification of NSAID's	6
1.2	Chemical structures of NSAID's	7
1.3	The conversion of arachidonic acid to prostaglandins	9
1.4	Schematic representation of the COX-2 active site	11
1.5	The structure of azapropazone	12
3.1	The design strategy for the proposed compounds under Series 1 and Series 2 using molecular hybridization approach	35
4.1	Possible mechanism of reaction for the synthesis of compounds **$S_1$4a– $S_1$4o**	39
4.2	Possible mechanism of reaction for the synthesis of compounds **$S_2$1a– $S_2$1e**	42
4.3	Possible mechanism of reaction for the synthesis of compounds **$S_2$2a– $S_2$2e**	43
4.4	Possible mechanism of reaction for the synthesis of compounds **$S_2$3a– $S_2$3e**	43
4.5	Possible mechanism of reaction for the synthesis of compounds **$S_2$4a– $S_2$4e**	44
5.1	Photomicrographs (10x magnification) of **[A]** Control; **[B]** Indomethacin; **[C]** Compound **$S_1$4d** and **[D]** Compound **$S_1$4e** treated groups in rat stomach tissues	75
5.2	Photomicrographs (10x magnification) of **[A]** Control; **[B]** Indomethacin; **[C]** Compound **$S_1$4d** and **[D]** Compound **$S_1$4e** treated groups in rat liver tissues	75
5.3	Photomicrographs (10x magnification) of **[A]** Control; **[B]** Indomethacin; **[C]** Compound **$S_1$4d** and **[D]** Compound **$S_1$4e** treated groups in rat kidney tissues	76
5.4	Lineweaver–Burk plot of *in vitro* COX–2 inhibition by potential derivatives of Series 1	80
5.5	3D view of the docking study of the minimum energy structure of the complex of **$S_1$4d** docked in COX–2 (PDB: 1CX2), viewed using the Glide XP visualiser of the Schrödinger Maestro 9.3 module	81
5.6	3D view of the docking study of the minimum energy structure of the complex of **$S_1$4e** docked in COX–2 (PDB: 1CX2), viewed using the Glide XP visualiser of the Schrödinger Maestro 9.3 module	81
5.7	Protein–ligand RMSD. RMSD evaluation of a protein (left *Y*–axis); the ligand RMSD (right *Y*–axis) indicating the stability of ligand **$S_1$4d** with respect to the protein and its binding pocket	83
5.8	The detailed atomic interactions of ligand **$S_1$4d** with the key	83

	amino acid residues at the active site of COX–2	
5.9	Stacked bar charts of protein interactions with ligand **$S_1$4d** as monitored throughout the MD simulation	83
5.10	Photomicrographs (10x magnification) of **[A]** Control group; **[B]**: Indomethacin; **[C]**: Celecoxib; **[D]**: Compound **$S_2$2d [E]**: Compound **$S_2$2e [F]**: Compound **$S_2$3c** treated groups in rat stomach tissues	103
5.11	Photomicrographs (10x magnification) of **[A]** Control; **[B]** Indomethacin; **[C]** Celecoxib **[D]** Compound **$S_2$2d [E]**: Compound **$S_2$2e [F]**: Compound **$S_2$3c** treated groups in rat liver tissues	104
5.12	Photomicrographs (10x magnification) of **[A]** Control; **[B]** Indomethacin; **[C]** Celecoxib **[D]** Compound **$S_2$2d [E]**: Compound **$S_2$2e [F]**: Compound **$S_2$3c** treated groups in rat kidney tissues	104
5.13	Lineweaver–Burk plot of *in vitro* COX-2 inhibition by compounds **$S_2$2c-$S_2$2e** and **$S_2$3c-$S_2$3e**	109
5.14	Overlay of docked pose of celecoxib (green) with its crystallographic conformation	113
5.15	3D view of the docking study of the minimum energy structure of the complex of **$S_2$2e** docked in COX-2 (PDB: 3LN1)	114
5.16	3D view of the docking study of the minimum energy structure of the complex of **$S_2$2d** docked in COX-2 (PDB: 3LN1)	114
5.17	3D view of the docking study of the minimum energy structure of the complex of **$S_2$2c** docked in COX-2 (PDB: 3LN1)	114
5.18	Minimum energy conformer for compounds **$S_2$4a- $S_2$4e**	115
5.19	Protein–ligand RMSD. RMSD evaluation of a protein (left *Y*–axis); the ligand RMSD (right *Y*–axis) indicating the stability of ligand **$S_2$2e** with respect to the protein and its binding pocket	117
5.20	The detailed atomic interactions of ligand **$S_2$2e** with the key amino acid residues at the COX-2 active site	117
5.21	Stacked bar charts of protein interactions with ligand **$S_2$2e** as monitored throughout the MD simulation	117